Mezavant Xl

Mesalazine, the active ingredient in Mezavant XL, is an aminosalicylate presented as an oral tablet formulation for oral use. It is employed to treat inflammatory bowel disease, particularly ulcerative colitis, by reducing gastrointestinal inflammation in adult patients. GNH USA supplies Mezavant XL as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mezavant XL is an aminosalicylate used in the management of ulcerative colitis and related inflammatory bowel conditions.

- Ulcerative colitis (induction): reduces colonic inflammation to achieve clinical remission. - Ulcerative colitis (maintenance): helps sustain remission and prevent relapse. - Inflammatory bowel disease (overall): controls disease activity in the colon, improving symptoms and quality of life.

Adverse reactions may occur with mesalazine therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal pain: cramping or discomfort in the abdomen. - Headache: transient mild headache. - Flatulence: increased intestinal gas. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Myocarditis: inflammation of heart muscle, requiring immediate medical attention. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Blood dyscrasias: including neutropenia or thrombocytopenia. - Pancreatitis: inflammation of the pancreas. - Interstitial nephritis: kidney inflammation that may impair function.

Patients should be monitored for safety considerations before and during therapy. - Renal function: assess kidney function and adjust use in renal impairment. - Hepatic function: monitor liver enzymes in patients with liver disease. - Blood counts: periodic complete blood count recommended. - Pregnancy: safety not established; discuss risks with a healthcare professional. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Mesalazine may interact with several medicines; clinicians should review patient regimens.

Major Interactions (Avoid): - Azathioprine: increased risk of bone‑marrow suppression. - Warfarin: potential enhancement of anticoagulant effect. - Methotrexate: additive toxicity, especially hepatic.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive efficacy. - Allopurinol: may raise plasma mesalazine levels, requiring monitoring.